Member Info for Tyke68

Can anybody (level 2 type people) confirm if the two blue trades were actually buys and also the 115k sell was that a sell or buy please?

Way the sp has dropped it seems like they should all be sells.

Just over 0.5% mcap traded and 8% drop. Sounds about right for this share.

Thanks in advance

Red are you buying up shares cheap again?

If not Red, then somebody is and MM’s helping with keep dropping the price

Thanks

Thanks malletp for all your insight it is appreciated

Have a good rest of the weekend

I think this is the key takeaway

“We remain open to partnership, licensing, or other structured arrangements that reflect the asset's underlying value, but our priority is organic growth in the core business. The same principle applies across the wider technology portfolio: we will advance and monetise these assets on terms that support long-term shareholder value, not near-term transactions at suboptimal valuations.”

So nothing is going cheap but we will need to wait for a return on our investments. As malletp says wait for the new clinical trial plus our data and then see what it’s worth then.

Thanks

Thanks Max

Not sure if we achieved anything but the board do now know we have over the 5% and no know how to contact the company secretary.

The new Modus Operandi would explain the lack of answers from Mike at times.

Anyway have a good weekend

Cheers

T

Sorry just noticed it says directors have taken less fees this year as well. Fees different from salaries?

Thanks

My initial reading of this is:

•the modus operandi is we will get less information but it will be more relevant when we do get it.

•We have had interest in the phase 1 data

•And everything else no real answers

I tried

Thanks

T

Continued

6. Can the revenue be broken down per customer eg MCW, GEHC, Blackford etc and other users?

We do not disclose revenue on a per-customer basis. Many of our client contracts include confidentiality provisions that restrict sharing customer-specific commercial terms, and broader disclosure would in any case expose our pricing to competitors — which is why per-customer reporting is not standard industry practice. Our reporting is structured at the portfolio level, where total revenue growth, customer retention, and account expansion give the clearest view of business momentum.

7. How long do we expect the collaboration with Vivan Therapeutics to continue for and have we had any feedback on how successful it has been and the possibility of it leading to generating revenues in the future?

The Vivan Therapeutics collaboration continues, but sits at an early, exploratory stage of drug discovery: Vivan's fruit-fly screening platform is positioned well before any path to revenue. Consistent with our broader focus, we have deprioritised internal drug development as a near-term commercial driver and are not forecasting material revenue from this work. We remain engaged with Vivan and view the relationship as longer-term optionality should early signals strengthen.

Dear all

I have just received these answers (I will let people make up their own opinions)

AGM Responses to Questions:

1. What exactly is the new modus operandi and how will it increase shareholder value back, and beyond, to where it was prior to the sale of significant shares to Braveheart (now Truetide)?

We recognise that disciplined, consistent communication matters. Going forward, we will provide updates only when supported by firm, validated data — not on earlier-stage developments or speculation. In the past, we shared progress on initiatives that ultimately took longer or required more investment than anticipated, and we understand the frustration this caused shareholders. Alongside this tighter disclosure approach, we are concentrating on fewer, higher-impact initiatives capable of delivering durable shareholder value, and we will report on them as results materialise.

2. What are the revenues for the first 3 months of 2026 compared to 2025 and what are the projected revenues for the year?

We don’t publish quarterly revenues, revenue forecasts if any, are made at the Interim and Annual reporting dates.

3. Have we had any discussions with other entities about the sale or licensing of our phase 1 data, and if so what valuation was discussed? Similarly any discussions on the sale of any of IB’s technology?

We have held selective discussions with external parties regarding the Phase 1 data; interest to date has been limited and no formal valuations have been tabled. We remain open to partnership, licensing, or other structured arrangements that reflect the asset's underlying value, but our priority is organic growth in the core business. The same principle applies across the wider technology portfolio: we will advance and monetise these assets on terms that support long-term shareholder value, not near-term transactions at suboptimal valuations.

4. Where have savings been made and what are the amounts saved?

The Company has materially reduced its cost base through specific actions: ending non-core service contracts, cutting external marketing spend, renegotiating supplier terms, and trimming discretionary expenditure. Directors have also accepted lower fees for the current year. With this leaner structure in place, we hope that any incremental revenue should flow largely to the bottom line.

5. Can the sales of software be broken down by product eg IB Neuro and what are the projected revenues per product?

IB Clinic is sold as a modular platform: clients combine different modules and procedural volumes within bundled contracts, so revenue is recognised at the contract level rather than per module. Consistent with industry practice, we do not break out module-level revenue, as it would expose pricing structure to competitors. The metric we manage to is platform-wide — total contract value and customer expansion — which we view as the more meaningful gauge of growth.

Have a good weekend everybody.

I can’t see us hearing anything before the AGM at this rate, unless there is something we don’t know about yet.

Thanks

T

Message from MS no update on phase 1 being published as of yet. He will share more when firm information.

Thanks

You can also now vote via the HL website, it has updated.

Thanks

Further update from Joe at Apex

“I have confirmation that we will receive responses to your questions by e-mail so that I can send you a copy of the responses.”

Let’s see what answers we get

Thanks

A reply from Apex

Yes, your questions are fine and will be presented to the AGM

So just a reminder of the questions we have asked:

AGM questions

• What exactly is the new modus operandi and how will it increase shareholder value back, and beyond, to where it was prior to the sale of significant shares to Braveheart (now Truetide)?

•What are the revenues for the first 3 months of 2026 compared to 2025 and what are the projected revenues for the year?

•Have we had any discussions with other entities about the sale or licensing of our phase 1 data, and if so what valuation was discussed? Similarly any discussions on the sale of any of IB’s technology?

•Where have savings been made and what are the amounts saved?

•Can the sales of software be broken down by product eg IB Neuro and what are the projected revenues per product?

•Can the revenue be broken down per customer eg MCW, GEHC, Blackford etc and other users?

•How long do we expect the collaboration with Vivan Therapeutics to continue for and have we had any feedback on how successful it has been and the possibility of it leading to generating revenues in the future?

I hope these are all ok for everyone involved. It will be interesting to see what answers we get. I am just awaiting confirmation the replies will be in the written AGM results RNS, unless somebody fancies a day trip to Jersey to hear them firsthand. It would be interesting to see if it is all done by teams or zoom etc or in person.

Thanks

T

Linandy

This is one of the question we are hoping will be asked at the AGM

“Can the sales of software be broken down by product eg IB Neuro and what are the projected revenues per product?”

Let’s see if we find out what they expect to earn from IB Neuro?

Still awaiting a reply from apex, I will let everyone know when I hear back

Thanks

Thanks Max

Maybe the company could explain how with all this excellent work by MCW that the share price of IBAI has been decimated? What is their plan to rectify this etc?

Thanks

According to HL you can vote via their website (not app please see below) but IBAI AGM doesn’t appear yet, I assume too soon.

Worryingly it also displayed how much I paid for my first IQAI shares, 9.4p in April 2021. That is quite a decimation of the price. How good it would be to get back to them prices.

“We don't automatically send out notification of shareholder meetings or voting forms to clients who hold shares in an HL Account.

However, this doesn't stop you from partaking or voting in any future AGMs on any of the shares that you hold. If you'd like to attend an AGM or vote on a company’s shares that you hold, you can do so once logged into your account through our website by clicking on the View shareholder meetings link underneath your secure messages.

From here, you will be able to see all upcoming shareholder meetings for companies in which you own shares and submit a vote on the proposals or request to attend an upcoming meeting.”

Malletp maybe you could ask when the expect the phase 1 results to be published please. A few of us seem to be persona non grata when speaking to the company after what happened in January and don’t always get replies. It has been 3 months since we know they were submitted to a journal. That seems a very long time to get no information.

Thanks in advance

T

Dr Marty Makary Has resigned from the FDA. Hopefully that will not have an effect on the vouchers as that could be a big selling point for the phase 1 data.

Thanks

Thanks MalletP

Max why haven’t the results being published in any journal yet. I honestly believe that is why the results and AGM are being delayed. But MCW/JC/CC are the leads so they control the narrative rather than IB. I still wonder if malletp has some inside information , no disrespect if you haven’t but your observations are very pertinent and thank you for them.

Thanks